Author

PAUL E. HEMSLEY

AstraZeneca (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

Abhishek SrivastavaiD· 1 shared David M. SmithiD· 1 shared E. L. RiversiD· 1 shared James D. RobinsoniD· 1 shared James L. TrevaskisiD· 1 shared Jon A. ReadiD· 1 shared JOSEFINE L. HANSENiD· 1 shared KARLY M. MATHERiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Abhishek SrivastavaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Direct β1/β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis

KARLY M. MATHER, Michelle L. Boland, E. L. Rivers, Abhishek Srivastava, Marianne Schimpl, PAUL E. HEMSLEY, James D. Robinson, Paul Wan, JOSEFINE L. HANSEN, Jon A. Read, James L. Trevaskis, David M. Smith

This study evaluates BI9774, an AMPK activator, in a mouse model of NASH, finding it reduces liver steatosis but not fibrosis and causes cardiac side effects.

bioRxiv · May 30, 2024 · PreprintPharmacology & Toxicology